| Popis: |
Background Never in Mitosis (NIMA)-related kinase 2 (Nek2), a member of the serine/threonine kinase family, localizes to centrosomes/kinetochores, which was involved in mitotic regulation. However, the clinical significance and the role of NEK2 in various cancers remained largely elusive. Methods ONCOMINE, Tumor Immune Estimation Resource (TIMER), Kaplan-Meier plotter database, UALCAN, GeneMANIA, String and CancerSEA Analysis were used to fully evaluate the clinical value of NEK2 Results NEK2 was meaningfully up-regulated in the vast majority of cancers, however, the prognostic significance of NEK2 was only associated with the patients with breast cancer, lung cancer, liver cancer, renal carcinoma, pancreatic ductal adenocarcinoma, sarcoma and thyroid carcinoma. Furthermore, NEK2 expression was also correlated with individual pathological cancer stages. In addition, NEK2 participated in regulating the tumor immunity. Enrichment analysis and functional state showed NEK2 was involved in the cell cycle. Conclusions These findings interpret the clinic value of NEK2 in a variety of cancers, which may be a novel biomarker and therapeutic target. |
